Latest Diabetic retinopathy Stories
The inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina, Medical College of Georgia researchers say.Ischemic retinopathy is characterized by uncontrolled formation of new blood vessels in the retina, and is seen in diseases such as diabetic retinopathy and retinopathy of prematurity. While this blood vessel formation, called neovascularization, can benefit ischemic heart disease and wound healing, it is bad in the...
PLAINVIEW, N.Y., Jan. 10, 2011 /PRNewswire/ -- Just in time for the new year, Davis Vision announces the launch of its new health and wellness program, the Eye Health Connection Program. With expanded coverage for eye exams and eyewear, it will offer cost savings, greater flexibility and enhanced benefits to members. Focusing on the four leading eye conditions - age-related macular degeneration, glaucoma, cataracts and diabetic retinopathy, Davis Vision's new program elevates benefits and...
TARRYTOWN, N.Y. and BERLIN, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO). In this trial, 56.1 percent of patients receiving VEGF Trap-Eye 2 milligrams (mg) monthly gained at...
TARRYTOWN, N.Y., Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time on Monday, December 20, to discuss results of the Phase 3 COPERNICUS study with VEGF Trap-Eye in central retinal vein occlusion (CRVO) and the week 52 follow-up results of the Phase 2 DA VINCI study in patients with diabetic macular edema (DME). A press release will be issued prior to the call....
A Statement from JDRF President and CEO, Jeffrey Brewer NEW YORK, Dec. 9, 2010 /PRNewswire-USNewswire/ -- "Today Congress passed a multi-year renewal of the Special Diabetes Program (SDP), ensuring that studies on promising diabetes treatments and avenues toward a cure continue uninterrupted. As the father of a son living with type 1 diabetes, and as CEO of JDRF, one of the leading advocates for the renewal of this program, I applaud the U.S. government for its continued commitment to end...
TARRYTOWN, N.Y. and BERLIN, Nov. 22, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare today announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every...
One drug's startling ability to restore retinal health in the eyes of diabetic mice has researchers wanting to learn more about how it works and whether it might do the same for people."We want to know if this drug has the potential to block the visual devastation that can occur with diabetes," said Dr. Sylvia Smith, retinal cell biologist and co-director of the Vision Discovery Institute at the Medical College of Georgia. "That means we need to know more about how and when it...
WASHINGTON, Nov. 1 /PRNewswire/ -- Group visits, telemedicine, peer counseling, and Internet-based education and case management are among the innovative strategies Department of Veterans Affairs (VA) researchers are studying to increase access to care and improve the health outcomes of Veterans and others with diabetes. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/va/46446/ VA researchers are seeking better ways to prevent and...
A recent study conducted by the American Academy of Ophthalmology estimates that nearly 188 million Americans suffer from vision impairments such as nearsightedness, farsightedness, and astigmatism. As patients return to work and school, Chester County Eye Care Associates is helping patients correct their vision impairments and prepare for fall with the range of eye care procedures they offer, including complete eye exams to screen for other common afflictions of the eye such as glaucoma,...
Oct. 17 AAO-MEACO Joint Meeting 2010 scientific program highlightsData on glaucoma risk in people with migraine and on innovative uses of mobile, digital technology are featured in today's Scientific Program, to be presented at the 2010 American Academy of Ophthalmology (AAO) "“ Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting. The AAO-MEACO meeting is in session October 16 through 19 at McCormick Place, Chicago. It is the largest, most comprehensive ophthalmic education...
